BICILLIN C-R 900/300 Rx
Generic Name and Formulations:
Penicillin G benzathine 900,000 units, penicillin G procaine 300,000 units; per syringe; susp for deep IM inj; contains parabens.
Indications for BICILLIN C-R 900/300:
Susceptible moderately severe infections including respiratory, skin and soft tissue, erysipelas, scarlet fever, otitis media.
Use other strengths.
Give by deep IM inj into midlateral thigh or buttock. Group A strep: one inj of 900/300 once. Pneumococcal: one inj of 900/300 every 2–3 days until afebrile for 48 hours.
Avoid intraarterial, intravascular, and intraneural inj.
Not for IV use. Do not admix with other IV solutions. Reports of inadvertent IV administration has been associated with cardiorespiratory arrest and death.
Not for IV use. Cephalosporin, imipenem, or other allergy: not recommended. Asthma. Monitor renal and hematopoietic function in prolonged use. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. May cause false (+) glucose test with Clinitest.
Rash, drug fever, serum sickness, anaphylaxis, blood dyscrasias, neuropathy, nephropathy, inj site reactions.
C–R Tubex 600,000 units/mL (1mL, 2mL)—10 (w. 1 inch or 1.25 inch needles); C–R disposable syringe 600,000 units/mL (4mL)—10 (w. 2 inch needles); C–R 900/300 Tubex 1.2 million units/syringe (2mL)—10 (w. 1 inch or 1.25 inch needles)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA Status Could Inform Pancreatic Cancer Management
- Polypharmacy and Cancer
- Adoptive Cell Therapy in Solid Tumors Demonstrates Robust Antitumor Effects
- Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma
- Heterogeneity of Drug Resistance in EGFR-Mutant Non-Small Cell Lung Cancer